[Skip to Navigation]
Sign In
November 23/30, 2021

Platelet-Rich Plasma for Osteoarthritis and Achilles Tendinitis

Author Affiliations
  • 1Orthopedic and Arthritis Center for Outcomes Research, Division of Rheumatology, Inflammation and Immunity, Department of Orthopedic Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
JAMA. 2021;326(20):2012-2014. doi:10.1001/jama.2021.19540

Symptomatic, radiographically documented knee osteoarthritis (OA) affects more than 14 million adults in the US and approximately 240 million worldwide,1,2 while symptomatic, radiographically documented ankle OA has been estimated to affect 3.4% of persons older than 50 years (approximately 3 million to 4 million adults older than 50 years in the US).3 Ankle OA develops typically in response to trauma (eg, fracture) and therefore often affects people in their active working years. Achilles tendinitis has an incidence estimated of approximately 2 per 1000 in the Netherlands4 and is associated with Achilles tendon rupture, an extremely disabling condition. These 3 conditions: knee OA, ankle OA, and Achilles tendinopathy, are costly and disabling, yet few effective therapies are available that relieve pain and also reverse underlying tissue damage.

Add or change institution